Holen Sie sich die Stockscreener-App
34.55
1.77%
0.60
Schlusskurs vom Vortag:
$33.95
Offen:
$34.59
24-Stunden-Volumen:
656.35K
Relative Volume:
1.27
Marktkapitalisierung:
$1.97B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-12.54
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
-5.45%
1M Leistung:
-12.44%
6M Leistung:
-28.54%
1J Leistung:
-0.14%
1-Tages-Spanne:
$32.54
$34.95
1-Wochen-Bereich:
$32.46
$37.22
52-Wochen-Spanne:
$32.46
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie APGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
34.55 | 1.97B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
(APGE) Trading Report - Stock Traders Daily
Interesting APGE Put And Call Options For October 17th - Nasdaq
Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month LowHere's What Happened - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Down 7.1%Here's Why - MarketBeat
Apogee Therapeutics' (APGE) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $608,700.00 in Stock - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.1% – What’s Next? - Defense World
Apogee Therapeutics Inc (APGE) presents a great opportunity, but the stock is slightly undervalued - US Post News
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics' chief medical officer sells $143,228 in stock - MSN
Apogee Therapeutics’ (APGE) Buy Rating Reaffirmed at Guggenheim - Defense World
Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 3,520 Shares of Stock - MarketBeat
Apogee Therapeutics CEO Michael Henderson sells $608,700 in stock - MSN
Apogee Therapeutics' chief medical officer sells $143,228 in stock By Investing.com - Investing.com Australia
Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,520 Shares - Armenian Reporter
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by Analysts - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average Target Price from Brokerages - Defense World
Market Watch: Apogee Therapeutics Inc (APGE)’s Noteworthy Drop, Closing at 40.37 - The Dwinnex
Should investors be concerned about Apogee Therapeutics Inc (APGE)? - US Post News
Apogee Therapeutics Advances APG777 in Key Phase 2 Trial - TipRanks
Apogee Therapeutics Announces First Patient Dosed in Part B - GlobeNewswire
Clinical Trial Breakthrough: Apogee's Novel Eczema Drug Draws Record Patient Interest - StockTitan
SG Americas Securities LLC Has $448,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 - Insider Monkey
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference - Marketscreener.com
Apogee's Management Reveals Latest Developments at Major Biotech Conference - StockTitan
Apogee Therapeutics: No Clinical Efficacy Data, Strong Competition, High Market Cap - Seeking Alpha
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by JPMorgan Chase & Co. - Defense World
(APGE) Investment Report - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 4.6%Should You Sell? - MarketBeat
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus.com
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $89.71 - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares - MarketBeat
Apogee Therapeutics CEO sells shares worth $732,692 By Investing.com - Investing.com Australia
Apogee Therapeutics CEO sells shares worth $732,692 - Investing.com India
Apogee Therapeutics (NASDAQ:APGE) Shares Down 9.1%What's Next? - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apogee Therapeutics Inc-Aktie (APGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Feb 05 '25 |
Sale |
40.69 |
3,520 |
143,229 |
252,623 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Feb 05 '25 |
Sale |
40.58 |
15,000 |
608,700 |
1,302,987 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):